Targeted Combo Plus Chemo Improves Survival in BRAF-Mutated CRC

By News Health
1 day Ago

(MedPage Today) — CHICAGO — First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF V600E-mutated metastatic colorectal…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115807

Author :

Publish date : 2025-05-29 19:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Immunotherapy drug doubles cancer survival in breakthrough trial

Experts Blast HHS Leaders for Defying Norms, Sidelining CDC

Biden Says He's 'Feeling Good' in First Remarks After Cancer Diagnosis Announced

CDC Drops Guidance for COVID Vaccines for Pregnancy

Higher-Than-Usual Number of Cardiovascular Deaths Part of COVID's Larger Picture

NHS Gets £750m Boost to Fix Crumbling Buildings